Diagnostic Accuracy of PSMA-targeted 18F-Florastamin PET/CT in Intermediate-risk Patients With Suspected Prostate Cancer

18F-Florastamin PSMA PET/CT demonstrated comparable diagnostic accuracy to mpMRI, with the added benefit of higher specificity. These findings suggest that PSMA PET/CT could complement mpMRI in the diagnostic evaluation of intermediate-risk prostate cancer, enhancing patient stratification and aiding clinical decision-making.